Regeneron Pharmaceuticals, Inc.’s stock price plunges to $568.91, marking a 6.87% drop: An in-depth analysis

Regeneron Pharmaceuticals, Inc. (REGN)

568.91 USD -41.95 (-6.87%) Volume: 2.62M

Regeneron Pharmaceuticals, Inc.’s stock price stands at 568.91 USD, experiencing a significant drop of -6.87% this trading session with a trading volume of 2.62M, and a notable YTD decrease of -20.13%, highlighting a potential opportunity for investors seeking value in the pharmaceutical sector.

Latest developments on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. faced a tumultuous day as its stock price sank due to Eylea Q1 sales falling short of estimates, leading to a 7% crash for the company’s blockbuster eye drug. Despite facing setbacks with FDA rejections and lower demand for Eylea, Regeneron navigated Q1 challenges with strategic growth plans and a $7 billion growth initiative as Dupixent and EYLEA HD sales surged. The company also received conditional EC approval for its bispecific antibody Lynozyfic in multiple myeloma, expanding its market reach. Regeneron’s first-quarter results missed expectations, causing stock prices to plummet, but brokerages still set a high price target of $950.76 for the company.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma